Spire Semiconductor Completes Phase I Solar Cell Program with NREL

Spire Corporation (Nasdaq: SPIR), a global solar company providing capital equipment and turnkey production lines to manufacture photovoltaic (PV) cells and modules, announced that its wholly owned subsidiary, Spire Semiconductor, LLC, has successfully completed Phase I of its High Efficiency Concentrator Solar Cell program with the Department of Energy’s National Renewable Energy Laboratory (NREL) and has been notified the NREL will authorized Phase II of the program.

Under the 18-month, $3.7 million cost share subcontract, Spire Semiconductor is developing technology to cost-effectively manufacture 42% efficient, 500 sun, concentrator solar cells for concentrator photovoltaic (CPV) systems.

Spire Semiconductor passed through the NREL Stage Gate Review, a go/no go decision point to validate the progression of the project and assure that progress meets contract objectives. These objectives include estimates of key performance parameters of competitive Levelized Cost of Energy (LCOE); annual manufacturing capacity potential; direct manufacturing cost; and cell Mean Time Between Failure (MTBF). PV cell performances of greater than 39% efficiency were achieved during Phase I.

“We are very happy to be given the go ahead with our program,” said Roger G. Little, Chairman and CEO of Spire Corporation. “It validates our efforts toward developing a proprietary gallium arsenide (GaAs) concentrator solar cell that exceeds anything commercially available.”

Mr. Little concluded, “The PV industry will continue to grow significantly this year and well into the future. CPV systems offer many advantages. With Spire’s strong position in the solar industry, the availability of our custom GaAs concentrator will put us in a good position to help our customers meet this market demand.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.